tirzepatide risk linked to lower for death, adverse CV and kidney outcomes vs. GLP-1s Tirzepatide Cuts Risk of Diabetes

Large observational studies have also linked GLP-1 receptor agonists with lower rates of alcohol, nicotine, cannabis, cocaine, and opioid-related disorders, along with reduced SUD-related hospitalizations and mortality

The peptide has FDA approval (as SCENESSE) specifically for erythropoietic protoporphyria, a non-malignant photosensitivity disorder, not for melanoma prevention

The data represents dose-response at 2 min and is normalized to the maximal GLP-1 response (100%)

Future research should prioritize the development of next-generation agonists, explore combination therapies, and integrate precision medicine approaches to optimize patient outcomes

Metabolic surgery and liver transplantation are therapeutic options for severe cases